Abstract In almost 30 years since the introduction of HMG-CoA reductase inhibitors (statins), no other class of lipid modulators has entered the market. Elevation of highdensity lipoprotein-cholesterol (HDL-C) via inhibiting cholesteryl ester transfer protein (CETP) is an attractive strategy for reducing the risk of cardiovascular events in high-risk patients. Transfer of triglyceride and cholesteryl ester (CE) between lipoproteins is mediated by CETP; thus inhibition of this pathway can increase the concentration of HDL-C. Torcetrapib was the first CETP inhibitor evaluated in phase III clinical trials. Because of off-target effects, torcetrapib raised blood pressure and increased the concentration of serum aldosterone, leading to higher cardiovascular events and mortality. Torcetrapib showed positive effects on cardiovascular risk especially in patients with a greater increase in HDL-C and apolipoprotein A-1 (apoA-1) levels. The phase III clinical trial of dalcetrapib, the second CETP inhibitor that has entered clinical development, was terminated because of ineffectiveness. Dalcetrapib is a CETP modulator that elevated HDL-C levels but did not reduce the concentration of low-density lipoprotein cholesterol (LDL-C). Both heterotypic and homotypic CE transfer between lipoproteins are mediated by some CETP inhibitors, including torcetrapib, anacetrapib, and evacetrapib, while dalcetrapib only affects the heterotypic CE transfer. Dalcetrapib has a chemical structure that is distinct from other CETP inhibitors, with a smaller molecular weight and a lack of trifluoride moieties. Moreover, dalcetrapib is a pro-drug that must be hydrolyzed to a pharmacologically active thiol form. Two other CETP inhibitors, anacetrapib and evacetrapib, are currently undergoing evaluation in phase III clinical trials. Both molecules have shown beneficial effects by increasing HDL-C and decreasing LDL-C concentration. The success of anacetrapib and evacetrapib remains to be confirmed upon the completion of phase III clinical trials in 2017 and 2015, respectively. Generally, the concentration of HDL-C has been considered a biomarker for the activity of CETP inhibitors. However, it is not clear whether a fundamental relationship exists between HDL-C levels and the risk of coronary artery diseases. The most crucial role for HDL is cholesterol efflux capacity in which HDL can reverse transport cholesterol from foam cells in atherosclerotic plaques. In view of the heterogeneity in HDL particle size, charge, and composition, the mere concentration of HDL-C may not be a good surrogate marker for HDL functionality. Recent clinical studies have reported that increased HDL functionality inversely correlates with the development of atherosclerotic plaque. Future development of CETP inhibitors may therefore benefit from the use of biomarkers of HDL functionality.
distinct from other CETP inhibitors, with a smaller molecular weight and a lack of trifluoride moieties. Moreover, dalcetrapib is a pro-drug that must be hydrolyzed to a pharmacologically active thiol form. Two other CETP inhibitors, anacetrapib and evacetrapib, are currently undergoing evaluation in phase III clinical trials. Both molecules have shown beneficial effects by increasing HDL-C and decreasing LDL-C concentration. The success of anacetrapib and evacetrapib remains to be confirmed upon the completion of phase III clinical trials in 2017 and 2015, respectively. Generally, the concentration of HDL-C has been considered a biomarker for the activity of CETP inhibitors. However, it is not clear whether a fundamental relationship exists between HDL-C levels and the risk of coronary artery diseases. The most crucial role for HDL is cholesterol efflux capacity in which HDL can reverse transport cholesterol from foam cells in atherosclerotic plaques. In view of the heterogeneity in HDL particle size, charge, and composition, the mere concentration of HDL-C may not be a good surrogate marker for HDL functionality. Recent clinical studies have reported that increased HDL functionality inversely correlates with the development of atherosclerotic plaque. Future development of CETP inhibitors may therefore benefit from the use of biomarkers of HDL functionality.
Introduction

Development of Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Numerous studies have identified a significant association between the concentration of high-density lipoprotein cholesterol (HDL-C) and the risk of coronary artery diseases (CAD) [1] [2] [3] [4] . Boosting the concentration of HDL-C thus appears to be an attractive strategy for atherosclerosis risk reduction [5] . Several drugs, including fibrates and niacin increase HDL-C levels without a definitive effect on cardiovascular risk [6] . Fibrates, including gemfibrozil, bezafibrate, fenofibrate and clofibrate, are a class of amphipathic carboxylic acids with lipid-modulating properties that include raising HDL-C levels [7] . The results of the Veterans Affairs HDL-C Intervention Trial (VA-HIT) showed that treatment with gemfibrozil reduced cardiovascular events by 24 % over a median follow-up of 5.1 years [8] . In contrast, the results of clinical studies with bezafibrate and fenofibrate were negative, and unfortunately clofibrate was associated with higher cardiovascular events [5] . In addition, the combination of HMGCoA reductase inhibitors (statins) with fibrates can increase the risk of rhabdomyolysis and subsequent acute renal failure [9] . Based on the variable results of clinical outcome studies and their safety concerns, the exact treatment position of fibrates remains uncertain [5] .
Niacin is the most effective current drug for elevation of HDL-C levels [10] . The Coronary Drug Project (CDP), one of the most influential niacin trials, evaluated niacin monotherapy in 8,341 patients with previous cardiovascular events. The result of this study showed that niacin decreased the incidence of nonfatal myocardial infarction by 27 % at 6 years, and total mortality was decreased by 11% at 15 years. In another clinical study, named the High-density lipoprotein Atherosclerosis Treatment Study (HATS) [82] , the combination of simvastatin and niacin was evaluated in CAD patients over a 3-year period. The results showed that the treatment group was associated with significant improvement in coronary artery atherosclerosis based on angiography and clinical markers. In general, niacin as monotherapy or in combination with other antihyperlipidemic drugs has a beneficial clinical effect on atherosclerosis. Unfortunately, at pharmacological doses, niacin exhibits numerous side effects that preclude the widespread use of niacin for increasing HDL-C levels [11] .
Cholesteryl ester transfer protein (CETP) is a plasma protein that naturally transfers cholesterol between lipoproteins, and more importantly from HDL-C to very low-density or low-density lipoproteins (VLDLs or LDLs) [12] . Thus, inhibition of the CETP would raise the concentration of HDL-C and may reduce the risk of CAD [13] .
To date, four CETP inhibitors, torcetrapib [14] , dalcetrapib [15] anacetrapib [16] , and evacetrapib [17] , have entered clinical development (Table 1) , and a few other agents are also in the development pipeline (BAY 60-5521 [18] and JNJ-28545595 [19] ). Figure 1 and Table 1 present  the chemical structure and physiochemical properties of  CETP inhibitors, respectively. In 2006, torcetrapib development was stopped prematurely because of increased mortality [20] . In May of 2012, Hoffmann-La Roche terminated a phase III trial of dalcetrapib on the recommendation of the Data and Safety Monitoring Board (DSMB) because of a lack of clinically meaningful efficacy [21] . Two other CETP inhibitors, anacetrapib and evacetrapib, are still undergoing development. This article analyses available pharmacological data on CETP inhibitors, with an emphasis on pharmacokinetic and pharmacodynamic properties of these agents, and will correlate these with the expected efficacy outcomes.
Physiological Actions of CETP
Triglyceride and cholesteryl ester (CE) transfer between lipoproteins is mediated by CETP [12] . A schematic diagram of cholesterol transfer by different mechanisms is shown in Fig. 2 . In the heterotypic CE transfer pathway, CE and triglyceride are moved between apolipoprotein B (apoB)-containing lipoproteins, including particles of VLDL or LDL and HDL. In the homotypic pathway, CE is transferred between sub-particles of HDL, including HDL3, HDL2, and pre-b HDL [22] . Both heterotypic and homotypic CE transfer between lipoproteins are affected by some CETP inhibitors, including torcetrapib, anacetrapib, and evacetrapib, while dalcetrapib affects the heterotypic transfer only. Shuttle and tunnel mechanisms are two main processes for neutral lipid transport between lipoproteins by CETP [23] . In the shuttle mechanism, CETP gathers CE molecules from one lipoprotein and transports these through the aqueous phase. In the tunnel mechanism, CETP mediates lipoprotein transport by forming a ternary complex [24] . [26] . Similarly, a prospective genome-wide association study in a cohort of 18,245 healthy women showed that several SNPs in the CETP gene were associated with an increase in HDL-C levels and reduced risk of future myocardial infarction [30] . Based on this evidence, the CETP pathway appears to be a good target for reducing the risk of cardiovascular events.
Pharmacological Properties of CETP Inhibitors
Torcetrapib
Torcetrapib was originally developed by Pfizer and tested in phase III clinical trials until its development was halted. Pfizer also investigated another CETP inhibitor, CP-800,569, but its development was also discontinued in 2008 for strategic reasons [31] . Torcetrapib binds to CETP with 1:1 stoichiometry and induces a non-effective complex between CETP and HDL-C. It inhibits both heterotypic and homotypic CE transfer pathways, resulting in the complete inhibition of CETP. Clinical studies have also shown that torcetrapib could slightly increase reverse cholesterol transport pathways [22] .
Pharmacokinetics
A summary of pharmacokinetic properties of torcetrapib and other CETP inhibitors is presented in Table 2 . Dalvie and colleagues [32] have described the results of a 21-daylong, mass balance study of orally administered of [ 14 C]torcetrapib at a dose of 120 mg. This article also contains information on pre-clinical and phase I studies of torcetrapib [32] . In healthy volunteers, the time to maximum concentration (t max ) of torcetrapib was approximately 6 h [32] . Average elimination half-lives were 373 and 211 h for total and unchanged torcetrapib radioactivity, respectively [32] . Torcetrapib was biotransformed to numerous metabolites mainly via oxidative biotransformation [32, 33] . The initial pathway for torcetrapib metabolism was decarbamoylation mediated by cytochrome P450 (CYP) 3A. Two metabolites, M1 (bistrifluoromethylbenzoic acid) and M4 (quinaldic acid), were identified as major metabolites in urine and plasma. In plasma, the concentration of M4 was threefold higher than torcetrapib concentration and *40 % of the dose was excreted as M4 and its glucuronide and urea conjugates in the urine. Only 7 % of the dose was excreted in urine as the M1 metabolite [32] . Moreover, in phase I studies, torcetrapib given to healthy subjects showed a non-linear increase in maximum concentration (C max ) and area under the concentration-time curve (AUC), with an increase in doses ranging from 10 to 1,000 mg [32] . Torcetrapib exposure was higher in fed than fasted healthy volunteers [32] . Pre-clinical pharmacokinetic studies in rat and monkey indicate that torcetrapib has an oral bioavailability of 33-45 % and a volume of distribution of 1.1-2.5 L/kg [32] .
Clinical Trials
The effect of torcetrapib on atherosclerosis was evaluated in three clinical studies: Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation (ILLUSTRATE) [34] and The Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor (RADIANCE 1) [35] and 2 [36] . The ILLUS-TRATE trial used intravascular ultrasound to evaluate coronary atheroma burden in patients with existing coronary atheroma [34] , whereas, RADIANCE 1 and 2 trials used B-mode ultrasound to evaluate the intima-media thickness in patients with dyslipidemia [35, 36] . The results of these studies showed torcetrapib increased HDL-C levels by *60 % and decreased low-density lipoprotein cholesterol (LDL-C) levels by *20 %. Torcetrapib had no beneficial effect on either atheroma burden in the coronary arteries [34] or carotid intima-media thickness [35, 36] . The Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLU-MINATE) study was a phase III trial aiming to investigate the effects of torcetrapib on cardiovascular outcomes [37] . Patients were randomized to take atorvastatin plus torcetrapib (60 mg) or atorvastatin plus placebo. Patients in the torcetrapib arm showed a 72 % increase in HDL-C concentration and moderate decreases in LDL-C and triglyceride levels. However, the primary endpoint of the trial, a composite of first major cardiovascular and cerebrovascular events, defined as death because of coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina, was 25 % higher in the torcetrapib group. Total mortality due to cardiovascular events or cancer and infections also increased in the torcetrapib arm. Torcetrapib adverse effects bear a resemblance to mineralocorticoid excess syndrome and included higher systolic blood pressure, serum aldosterone, sodium and bicarbonate levels but a lower serum potassium level [37] .
The underlying mechanisms of increased cardiovascular mortality in the ILLUMINATE trial are still not entirely determined, but the effect of torcetrapib on aldosterone levels is the most notable 'off-target' effect of this drug. Expression of several renin-angiotensin-aldosterone system genes, in arteries and adrenal glands, can be up-regulated and the production of mineralocorticoid hormones can be induced by torcetrapib. The pressor effect of torcetrapib may be mediated by several actions of adrenal glands through the calcium pathway. Several studies showed that torcetrapib increased synthesis of aldosterone and cortisol in vitro. Aldosterone can induce hypertension and directly generate endothelial dysfunction, increased vascular smooth-muscle migration, myocardial fibrosis, and increased inflammation in the cardiovascular system. The possibility that elevation of aldosterone levels may be related to torcetrapib adverse effects was supported by the observation of a higher mortality from cardiovascular events in patients with greater changes in serum potassium and bicarbonate levels [38] .
There is also evidence for beneficial effects of torcetrapib. The result of post hoc analysis in the ILLUMINATE trial showed that lower cardiac events were seen in the patient group with a higher increase in HDL-C and apoA-1 [37] . Torcetrapib with 60 mg daily did not alter cholesterol efflux capacity through the ABCG1 pathway, and with 120 mg daily, increased HDL functionality via the previously mentioned pathway [20, 39] . Post hoc analysis of the ILLUSTRATE trial revealed a regression of coronary atheroma in torcetrapib-group patients with HDL-C concentrations in the upper quartile [39] .
Dalcetrapib
Dalcetrapib is a thioester pro-drug ( Fig. 1 ) with a structure that is distinct from other CETP inhibitors (smaller molecular weight and lack of trifluoride moiety). It is hydrolyzed by non-specific esterases and lipases in the biological media to generate a pharmacologically active thiol form [40] . It modulates the activity of CETP by the formation of a disulfide bond at the cytosine residue and induction of a conformational change in this protein [41] . Dalcetrapib inhibits heterotypic rather than homotypic CE transfer resulting in the partial inhibition of CETP. Through this mechanism, the homotypic CE transfer that produces larger HDL2 and smaller pre-b HDL from HDL3 will not be affected by dalcetrapib [22] .
Pharmacokinetics
Dalcetrapib is well tolerated and exhibits dose-proportional pharmacokinetics up to a dose of 4,500 mg/day [42] . Dalcetrapib is rapidly hydrolyzed to generate dalcetrapibthiol, which is pharmacologically active. Dalcetrapib-thiol covalently binds to CETP and to other plasma proteins, but the compound is cleared with a relatively short half-life (t 1/2 25.5 h) thus generating a relatively transient change in CETP activity [43] . The hydrolysis of dalcetrapib to dalcetrapib-thiol is mediated by non-specific esterases and lipases [40] . Dalcetrapib-thiol is further biotransformed to two major metabolites: dalcetrapib-S-methyl and dalcetrapib-S-glucuronide metabolites [44] . Dalcetrapib exposure was significantly higher (*65 %) in fed versus fasted state [45] . In comparison with a standard meal, exposure to dalcetrapib was *15 % lower after a light meal but was *35 % higher after a high-fat meal [45] . Co-administration of the anti-obesity agent orlistat (doses 10-120 mg) with dalcetrapib (600 mg) reduced dalcetrapib exposure by more than 50 % at all dose levels except for 10 mg of orlistat [40] . The activity of CETP, measured ex vivo, was also pronouncedly reduced upon co-administration with orlistat [40] . Orlistat is a potent inhibitor of carboxylesterase-2, an enzyme expressed abundantly in the gastrointestinal tract and liver and is subjected to genetic polymorphism [46] .
Drug interactions with dalcetrapib have been studied extensively. Dalcetrapib administration with statins, simvastatin, rosuvastatin, and pravastatin was well-tolerated [47] . Dalcetrapib exposure was significantly lower when co-administered with simvastatin and rosuvastatin, but it was not different when co-administered with pravastatin [47] . Statin exposure was not influenced by dalcetrapib coadministration except for lower exposure to rosuvastatin [47] . Co-administration of dalcetrapib and atorvastatin did not result in clinically meaningful changes in the pharmacokinetics of either drug [48] . Moreover, administration of ezetimibe with dalcetrapib did not generate a significant drug-drug interaction [49] . Dalcetrapib did not interact with monophasic oral contraceptives Microgynon Ò 30 (ethinylestradiol 0.03 mg/levonorgestrel 0.15 mg) [50] . Co-administration of a uridine 5'-diphospho-glucuronosyltransferase (UDP)-glucuronosyltransferase (UGT) inhibitor probenecid with dalcetrapib increased the AUC from time zero to infinity (AUC ? ) and C max of dalcetrapibthiol by 14 and 21 %, respectively [51] .
Clinical Trials
The dal-HEART program included a series of phase II and III clinical studies aiming to evaluate the efficacy and safety of dalcetrapib in humans. The dal-VESSEL [52] and dal-PLAQUE [53] were the most notable trials in this program.
The dal-PLAQUE trial evaluated the effect of dalcetrapib on atherosclerotic plaques in 130 patients with CAD or a high risk for a cardiovascular disease. Patients were randomized to take dalcetrapib 600 mg daily or placebo in addition to standard medical treatment for 24 months. Total vessel area, wall area, normalized carotid artery wall index, and arterial inflammation within an index vessel were not different between groups. However, dalcetrapib significantly reduced the magnetic resonance imagingderived change in total vessel area compared with placebo. Arterial inflammation was evaluated by the use of 18 Ffluorodeoxyglucose ( 18 F-FDG), a radiopharmaceutical commonly used in imaging with positron emission tomography. While dalcetrapib did not have any significant effect on arterial inflammation, a post hoc analysis, limited to the carotid artery, showed dalcetrapib significantly reduced arterial inflammation in the most diseased segments [53] .
The dal-VESSEL trial evaluated dalcetrapib's safety profile and the effect of dalcetrapib on endothelial function in 476 patients with CAD or cardiovascular risk equivalent for 36 weeks. Patients were randomized to receive dalcetrapib or placebo in addition to standard medical treatment. Changes in flow-mediated dilation (FMD percent) of the right brachial artery and 24 h ambulatory blood pressure monitoring, markers of inflammation, oxidative stress, and coagulation were evaluated at different times during the 36 weeks. At the study's completion, HDL-C levels had increased by 31 % but LDL-C levels had not changed significantly. When compared with placebo, dalcetrapib had no effect on FMD after either 12 or 36 weeks of treatment. Dalcetrapib had no effect on ambulatory blood pressure up to 36 weeks of treatment. Biomarkers of inflammation, oxidative stress, and coagulation were unaffected by dalcetrapib, although the concentration of lipoprotein-associated phospholipase A2 (Lp-PLA2) was increased by 17 % in those taking dalcetrapib [52] .
The dal-OUTCOMES were a series of phase III clinical studies involving 15,600 patients aiming to evaluate the efficacy and safety of dalcetrapib in patients with acute coronary syndrome [15] . Patients were randomized to take dalcetrapib or placebo. This trial was designed to continue until the occurrence of 1,600 primary outcomes, with an anticipated conclusion in 2013. However, it was reported in May of 2012 that the dal-OUTCOMES trial had been prematurely terminated by an independent DSMB because of an apparent lack of efficacy [21] . Subsequently, Hoffmann-La Roche has discontinued the entire dalcetrapib development program (dal-HEART).
The recently published dal-OUTCOMES trial showed that dalcetrapib significantly increased HDL-C and apoA-1 levels but had no effect on LDL-C concentration [54] . Dalcetrapib did not alter the risk of major cardiovascular events since cumulative event rates were 8.0 and 8.3 % for dalcetrapib and placebo, respectively (p = 0.52). Although, dalcetrapib had an acceptable adverse-effect profile, the drug significantly increased systolic blood pressure and the concentration of C-reactive protein [54] .
Three probable reasons for the termination of the dal-OUTCOMES trial have been proposed: (1) the increase in HDL-C level is not accompanied by an improvement in the HDL-C atheroprotective effects or HDL binding capacity; (2) it is possible that the favorable effect of dalcetrapib on HDL-C levels were counterbalanced by adverse events such as increased blood pressure; and (3) the atheroprotective effect of HDL-C observed in clinical studies is an epiphenomenon rather than a true protective effect against coronary vascular disease.
Anacetrapib
Similar to torcetrapib, anacetrapib inhibits both heterotypic and homotypic CE transfer. Inhibition of homotypic CE transfer by anacetrapib may restrict the elevation of HDLmediated reverse cholesterol transport. However, the clinical importance of this mechanism is unclear [22] . Anacetrapib is currently undergoing clinical development by Merck & Co.
Pharmacokinetics
Oral absorption of anacetrapib was rapid with a t max of *4 h [55] similarly rapid inhibition of serum CETP activity was observed, reaching maximum inhibition at *4 h post dose. The activity of CETP was inhibited by approximately 80 % by 24 h post dose [56] . Feeding status significantly influenced anacetrapib exposure, resulting in a two-to threefold increase in the exposure after a low-fat meal and a six-to eightfold increase after a high-fat meal [55] . The values of elimination half-life were 9-62 h in the fasted volunteers and 42-83 h in fed volunteers [55] . There was an apparent plateau in the oral absorption of higher doses [55] . Pharmacokinetic and pharmacodynamic properties of anacetrapib were comparable with respect to age, sex, and obesity [55] .
Pre-clinical pharmacokinetic studies of anacetrapib in rats and rhesus monkeys showed an oral bioavailability of 38 and 13 %, respectively. The AUC was not dose proportional between 1 and 500 mg/kg, possibly related to limited water solubility at higher doses [57] . After oral administration of [
14 C] anacetrapib, *90 % of the dose was recovered within 48 h. The recovered anacetrapib was mainly unchanged in feces and via biliary excretion (*15 %) and urine (\2 %). Metabolism included the formation of oxidative and glucuronidated metabolites. The main metabolites included of an O-demethylated product (M1), hydroxylated on the biphenyl moiety (M2) or on the isopropyl side chain (M3), followed by glucuronidation of oxidative metabolites [57] .
A mass balance study in six healthy male volunteers using 150 mg of [ 14 C]anacetrapib was reported by Kumar et al. [58] . Similar to pre-clinical studies, fecal excretion was the main route of elimination. In general, anacetrapib seems to have a low to moderate oral absorption and the fraction of the drug reaching the systemic circulation is mainly eliminated as oxidative metabolites via the biliary/ fecal route [58] .
Anacetrapib drug interactions with simvastatin [59] , digoxin [60] , warfarin [61] , the CYP3A4 substrate midazolam [62] , and the CYP3A4 inhibitor ketoconazole [62] were studied. Anacetrapib (150 mg) did not influence midazolam clearance [62] . However, anacetrapib exposure was increased by 4.5-fold when it was given with 400 mg ketoconazole, thus indicating that anacetrapib is a substrate but not an inhibitor of CYP3A4 [62] . Co-administration of anacetrapib with simvastatin (40 mg), which is also a CYP3A4 substrate, resulted in an *30 % increase in exposure to simvastatin lactone (the administered form) and simvastatin acid (active drug) [59] . Anacetrapib did not meaningfully affect the exposure to digoxin, a cardiovascular agent, and a known P-glycoprotein substrate [60] . Moreover, anacetrapib did not influence the pharmacokinetics or pharmacodynamics of the anticoagulant agent warfarin, which is a CYP2C9 substrate with narrow therapeutic index [61] .
Population pharmacokinetic and pharmacodynamic modeling revealed that a maximum effect model (E max ) describes the relationship between anacetrapib concentration and changes in HDL-C and LDL-C. The estimated E max for increase in HDL-C was 160 %, and EC 50 (effective concentration for half-maximum response) was 0.22 lmol/L [56].
Clinical Trials
In patients with dyslipidemia, anacetrapib monotherapy increased HDL-C by 129 % and reduced LDL-C by 38 % dose dependently without affecting ambulatory blood pressure [16] . Yvan-Charvet et al. [63] evaluated the effects of niacin and anacetrapib on lipid profiles and the ability of HDL to promote net cholesterol efflux. Anacetrapib effectively increased HDL-C, and decreased LDL-C levels and improved HDL 0 s cholesterol efflux capacity from macrophages [63] . The efficacy and safety of anacetrapib was evaluated in a clinical trial named DEFINE [64] . A total of 1,623 patients with CAD or at high risk for CAD on statin therapy were randomized to receive anacetrapib or placebo for 18 months. After 24 weeks of treatment, anacetrapib decreased LDL-C by 40 % and increased HDL-C by 138 % as compared with placebo. Despite pronounced elevation of HDL-C, C-reactive protein levels did not change significantly. Furthermore, anacetrapib had no 'offtarget' adverse effects like torcetrapib through 76 weeks of treatment [64] . Moreover, administration of anacetrapib at 150 mg daily to 30 healthy individuals resulted in a significantly lower concentration of medium and small VLDL, and medium and small LDL (LDL2a, 2b, and 3a) [65] . The presence of small, dense LDL particles is associated with the risk of development of ischemic heart disease [66] .
The REVEAL study (ClinicalTrials.gov Identifier: NCT01252953) is a phase III clinical trial aiming to recruit approximately 30,000 patients with CAD. Its objective is to evaluate the effectiveness of anacetrapib on cardiovascular events through 4 years of follow-up. This study was started in 2011 and has an excepted completion date of 2017.
Evacetrapib
Evacetrapib is a CETP inhibitor currently undergoing development by Eli Lilly and Company. It has a similar structure and mechanism of action to torcetrapib but, based on IC 50 values, appears to be a more potent CETP inhibitor than torcetrapib or anacetrapib [17, 67] . However, the underlying mechanism of evacetrapib's effect on HDLmediated reverse cholesterol transport and heterotypic and homotypic CE transfer has not been elucidated [22] .
Pharmacokinetics
Currently no information is available in the published literature on evacetrapib pharmacokinetics.
Clinical Trials
The efficacy and safety of evacetrapib was evaluated in a phase II clinical study involving 398 dyslipidemic patients with elevated LDL-C or low HDL-C levels (ClinicalTrials.gov Identifier: NCT01105975). Evacetrapib was taken either alone or in combination therapy with statins. The patients were randomized to receive evacetrapib monotherapy at doses of 30, 100, and 500 mg daily or placebo for 3 months. Moreover, the effect of evacetrapib 100 mg daily was evaluated in 239 patients who were taking statins. In comparison with placebo, evacetrapib monotherapy reduced LDL-C levels by 14-36 % and increased HDL-C levels by 54-129 % in a dose-dependent manner. In addition, evacetrapib in combination therapy with statins elevated HDL-C plasma concentrations similar to evacetrapib monotherapy but had an additional reduction of LDL-C levels of 11-14 % compared with statin monotherapy. Evacetrapib did not show off-target adverse effects similar to torcetrapib [68] . Recently, Eli Lilly and Company has started a phase III clinical trial named ''A Study of Evacetrapib in High-Risk Vascular Disease, ACCELER-ATE,'' with an estimated enrolment of 11,000 patients (ClinicalTrials.gov Identifier: NCT01687998).
Is There a Future for CETP Inhibitors?
The failure of torcetrapib challenged the notion of favorable effect of CETP inhibitors on cardiovascular events mediated by increasing the concentration of HDL-C. However, 'off-target' effects of torcetrapib that are unrelated to CETP inhibition could potentiate these side effects. A decisive argument supporting this hypothesis is that other CETP inhibitors do not exhibit torcetrapib-like adverse effects [39] .
In addition, based on prior knowledge, it could not be predicted that a seemingly safe molecule like dalcetrapib could lack adequate efficacy. Dalcetrapib induced a modest increase in HDL-C levels but did not decrease LDL-C levels. Individuals with the CETP genetic variation and a lower risk of CAD often have a higher concentration of HDL-C and lower LDL-C [69] . Therefore, it is possible that for achieving a desired clinical outcome, it is necessary to select a CETP inhibitor that affects both HDL-C and LDL-C concurrently.
Dalcetrapib has a distinct structure and unique mechanism of action. It only raises HDL-C but does not affect the concentration of LDL-C. Some aspects of dalcetrapib pharmacokinetics including the need for the bioactivation of the molecule to the thiol and the relatively short elimination half-life of dalcetrapib-thiol may render the drug ineffective in a portion of the population and thus may explain the failure of this drug in phase III clinical trials.
Anacetrapib and evacetrapib are parent drugs without the need for the bioactivation. Both agents not only increase HDL-C effectively but also decrease LDL-C concentration by more than 30 %. This may provide a strong motivation for carrying out of clinical trials with these CETP inhibitors. Finally, we should consider that even if positive results are demonstrated in future studies it may be difficult to determine whether the beneficial clinical outcome is due to HDL-C increase or LDL-C lowering or other effects.
Is HDL-C Level Still a Real Risk Factor and Practical
Therapeutic Target?
Patients with atherosclerosis typically present with a low concentration of HDL-C [1, 70] . However, it is not clear whether a fundamental association exists between HDL-C and the risk of CAD. Some studies have reported genetic variants related to HDL-C levels correlated with cardiovascular disease [71] [72] [73] . Recently, a Mendelian randomization study was carried out to evaluate the association between plasma HDL-C and the risk of cardiovascular events [69] . This study reported that some genetic mechanisms including polymorphism in endothelial lipase gene and 14 other SNPs commonly associated with high HDL-C level did not reduce the risk of cardiovascular events [69] . These data challenge the concept that low HDL-C level is a real risk factor for CAD.
The most crucial role for HDL is cholesterol efflux capacity, which consists of several pathways such as ABCA1, ABCG1, scavenger receptor class B member 1 (SR-B1), and aqueous diffusion. Through these pathways, HDL could reverse transport cholesterol from foam cells in atherosclerotic plaques. HDL functionality is defined as the capacity of HDL to promote cholesterol reverse transport by accepting cholesterol from foam cells.
Functionality of HDL, independent of its concentration, could determine atherosclerotic burden [6, 74] . Recently, Khera et al. [6] carried out a clinical study for the evaluation of the association between HDL functionality and development of atherosclerotic plaques. Atherosclerosis development was evaluated by carotid intima-media thickness and coronary artery angiography. They reported a strong inverse association between atherosclerotic development and HDL functionality determined by cholesterol efflux capacity from macrophages, and this association was independent of the HDL-C level. Therefore, application of this functional biomarker may be more informative than the concentration of plasma HDL-C [75, 76] .
In view of the heterogeneity in HDL particle size, charge, and composition, the mere concentration of HDL-C is not a good surrogate marker for HDL functionality [6] . Moreover, cholesterol efflux is also carried out by several other pathways including aqueous diffusion, ABCG1, SR-B1 and ABCA1 [77] , and the cholesterol efflux capacity assay used in Khera et al. [6] measures the total cholesterol efflux from macrophages.
Several studies have shown a significant and reproducible association between risk factors of cardiovascular disease and HDL-C related esterase/lactonase paraoxonase 1 (PON1) [78, 79] . This pathway is associated with the anti-inflammatory and antioxidant properties of HDL. Genetic studies that have shown an association between PON1 and CAD risk and oxidative stress support its selection as an HDL functionality assay [6, 79] . HDL has a variety of functions such as antioxidant, anti-inflammatory, anti-thrombogenic, and atheroprotective activities, although not all of them, are related to atheroprotection [80] . Therefore, a mechanistic approach for determination of HDL functionality may be useful for future clinical trials and better evaluation of HDL 0 s role in CAD. In future clinical studies, it is advisable to use a measure of cholesterol efflux capacity by HDL, in addition to HDL-C level, as a biomarker of effect for CETP inhibitors. The pragmatic issues associated with conducting a functional assay on a large scale will remain an obvious challenge of the use of this biomarker.
Concluding Remarks
No other class of lipid modulators has been introduced in approximately 30 years since the introduction of the first statin, lovastatin [81] . Inhibition of CETP pathway remains an attractive mechanism of action for a novel class of cardiovascular agents. However, failure of the first two drugs in this category questions the future of this class of drugs. It transpires that torcetrapib's failure was because of off-target effects, not because of CETP inhibition. Dalcetrapib's failure could be attributed to several factors including transient CETP modulation by dalcetrapib-thiol and the pharmacokinetic variability associated with dalcetrapib activation. Two other agents in this class are undergoing clinical development, and they have shown promising results in phase I and II clinical trials. The success of anacetrapib and evacetrapib will remain to be confirmed after the completion of REVEAL and ACCEL-ERATE studies, in 2017 and 2015, respectively.
